CD274 and neoplasm: These observations indicate the potential benefit of further exploring the role of DDR GAs and the use of recognised predictive biomarkers of immunotherapy to appropriately stratify patients based on tumour mutational burden (TMB), microsatellite instability (MSI) and PD-L1 expression12–14.